{
    "pmcid": "10588750",
    "qa_pairs": {
        "What is the primary target for neutralizing antibodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD) and the N-terminal domain (NTD) of the S1 subunit",
            "The S2 subunit of the spike protein",
            "The transmembrane domain of the spike protein",
            "The cytoplasmic tail of the spike protein"
        ],
        "What method was used to confirm the binding affinity of Nb-H6 to the spike protein?": [
            "ELISA and Biolayer Interferometry (BLI)",
            "Western Blotting and Mass Spectrometry",
            "Flow Cytometry and Surface Plasmon Resonance",
            "X-ray Crystallography and NMR Spectroscopy"
        ],
        "What potential therapeutic application is suggested for Nb-H6 due to its stability and efficacy?": [
            "Inhalable formulations to target the virus in the respiratory tract",
            "Intravenous administration for systemic treatment",
            "Topical application for skin infections",
            "Oral administration for gastrointestinal infections"
        ],
        "Which conserved residues on the RBD does Nb-H6 bind to, preventing ACE2 interaction?": [
            "Tyr449 and Tyr489",
            "Ser477 and Thr478",
            "Asp614 and Gly681",
            "Phe486 and Leu452"
        ],
        "Which nanobody was developed to neutralize SARS-CoV-2 and its variants?": [
            "Nb-H6",
            "Nb-A1",
            "Nb-C3",
            "Nb-F9"
        ]
    }
}